Profit-Alert: Follow the Smart Money in the Global EV Boom
The Electric Vehicle boom is here! This upstart lithium developer is positioning to be a future supplier to Tesla’s Gigafactory in the Nevada desert. Best of all, it’s currently undiscovered by Wall Street below US$1 per share.
Click here for details...
pixel
Rodger  Novak, insider at CRISPR Therapeutics

Rodger Novak Insider Information

President of CRISPR Therapeutics

Dr. Rodger Novak is the co-founder, president and chairman of CRISPR Therapeutics, a Switzerland-based biotechnology company he helped found in 2013. 

Since its inception in 2013, Dr. Novak has been at the helm of CRISPR and its emerging technologies. From 2013 to 2017 Dr. Novak served as the company’s CEO, helping turn CRISPR into a clinical stage company by building up its U.S.-based operations to more than 150 employees and taking the company public in 2016.

During his tenure as CEO, Dr. Novak helped raise more than $400 million in capital, established a joint venture with Bayer and closed a multi-billion dollar deal with Vertex Pharmaceuticals. 

He left his position as CEO in December 2017 to serve as the company’s president and chairman of the board. He also serves as the director of Casebia Therapeutics, CRISPR’s joint venture with Bayer AG. 

Dr. Novak was a serial entrepreneur and experienced pharmaceutical and biotechnology executive long before CRISPR’s founding. He previously served as the global head of infectious disease and research and development with Sanofi, based in Paris. While there, he was tasked with discovery and R&D around antibiotics, antivirals and drugs for the diseases present in the developing world. 

In 2006, he co-founded Nabriva Therapeutics, an antibacterial development company operating out of Vienna, Austria. He served as chief operating officer at Nabriva for almost six years. Dr. Novak’s career began at Sandoz, where he worked as the deputy head of the antibiotic research institute. Nabriva is largely a spin-off of Dr. Novak’s work at Sandoz. 

He is also a former professor of microbiology at the Vienna Biocenter in Austria. He earned his M.D. from Philipps University in Marburg, Germany and his U.S. medical license the following year. Dr. Novak continued his post-doctoral work in New York City, serving at The Rockefeller University, St. Jude’s Children’s Research Hospital and the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center. 

He is listed as co-inventor for five patents, and he has authored articles for Nature, Molecular Cell, and Nature Medicine

What is Rodger Novak's net worth?

The estimated net worth of Rodger Novak is at least $89.88 million as of November 30th, 2020. Dr. Novak owns 698,007 shares of CRISPR Therapeutics stock worth more than $89,875,381 as of June 14th. This net worth estimate does not reflect any other assets that Dr. Novak may own.

How old is Rodger Novak?

Dr. Novak is currently 54 years old. There are 5 older executives and no younger executives at CRISPR Therapeutics. The oldest executive at CRISPR Therapeutics is Mr. Michael John Tomsicek, Chief Financial Officer, who is 55 years old.

How do I contact Rodger Novak?

The corporate mailing address for Dr. Novak and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at 41-41-561-3277 and via email at [email protected]

Has Rodger Novak been buying or selling shares of CRISPR Therapeutics?

Rodger Novak has not been actively trading shares of CRISPR Therapeutics within the last three months. Most recently, Rodger Novak sold 100,000 shares of the business's stock in a transaction on Monday, November 30th. The shares were sold at an average price of $125.00, for a transaction totalling $12,500,000.00. Following the completion of the sale, the president now directly owns 698,007 shares of the company's stock, valued at $87,250,875.

Who are CRISPR Therapeutics' active insiders?

CRISPR Therapeutics' insider roster includes Kurt Emster (Director), and Rodger Novak (President).

Are insiders buying or selling shares of CRISPR Therapeutics?

In the last year, insiders at the sold shares 23 times. They sold a total of 778,323 shares worth mmore than $97,135,551.29. The most recent insider tranaction occured on March, 22nd when Bradley J Phd Bolzon Director bought 30,374 shares worth more than $4,020,606.38. Insiders at CRISPR Therapeutics own 21.4 % of the company.

Information on this page was last updated on 3/22/2021.

Rodger Novak Insider Trading History at CRISPR Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2020Sell100,000$125.00$12,500,000.00698,007View SEC Filing Icon  
9/1/2020Sell25,000$92.62$2,315,500.00651,940View SEC Filing Icon  
7/7/2020Sell25,000$90.00$2,250,000.00653,593View SEC Filing Icon  
6/23/2020Sell50,000$75.00$3,750,000.00698,007View SEC Filing Icon  
5/19/2020Sell50,000$65.00$3,250,000.00798,007View SEC Filing Icon  
11/19/2019Sell33,618$70.00$2,353,260.0033,618View SEC Filing Icon  
7/10/2019Sell50,000$50.00$2,500,000.00848,007View SEC Filing Icon  
6/10/2019Sell50,000$45.00$2,250,000.00898,007View SEC Filing Icon  
3/4/2019Sell85,220$40.40$3,442,888.001,024,534View SEC Filing Icon  
3/1/2019Sell8,693$40.01$347,806.931,024,534View SEC Filing Icon  
2/25/2019Sell14,780$40.00$591,200.001,033,227View SEC Filing Icon  
1/8/2019Sell17,310$35.09$607,407.901,130,697View SEC Filing Icon  
5/17/2018Sell75,000$60.00$4,500,000.001,183,247View SEC Filing Icon  
9/5/2017Sell18,470$20.76$383,437.201,148,007View SEC Filing Icon  
8/30/2017Sell75,795$20.25$1,534,848.751,232,697View SEC Filing Icon  
6/22/2017Sell10,825$15.37$166,380.251,225,830View SEC Filing Icon  
6/21/2017Sell30,222$15.01$453,632.221,230,397View SEC Filing Icon  
6/9/2017Sell5,303$15.02$79,651.061,219,208View SEC Filing Icon  
5/30/2017Sell3,650$15.02$54,823.001,218,655View SEC Filing Icon  
5/17/2017Sell50,000$16.26$813,000.001,239,082View SEC Filing Icon  
5/5/2017Sell616$16.92$10,422.721,215,621View SEC Filing Icon  
5/4/2017Sell49,384$16.30$804,959.201,230,929View SEC Filing Icon  
4/20/2017Sell50,000$17.88$894,000.001,262,711View SEC Filing Icon  
See Full Table

Rodger Novak Buying and Selling Activity at CRISPR Therapeutics

CRISPR Therapeutics Company Overview

CRISPR Therapeutics logo
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in the development of regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. It also has a strategic partnership with Nkarta, Inc. to research, develop, and commercialize CRISPR/Cas9 gene-edited cell therapies for cancer. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Read More

Today's Range

Now: $128.76
$127.30
$130.39

50 Day Range

MA: $118.09
$100.84
$135.72

2 Week Range

Now: $128.76
$59.19
$220.20

Volume

1,091,267 shs

Average Volume

1,880,785 shs

Market Capitalization

$9.76 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.26
Profit-Alert: Follow the Smart Money in the Global EV Boom
The Electric Vehicle boom is here! This upstart lithium developer is positioning to be a future supplier to Tesla’s Gigafactory in the Nevada desert. Best of all, it’s currently undiscovered by Wall Street below US$1 per share.
Click here for details...
pixel